Recro Pharma's pain treatment clears Phase II; GSK and Immunocore move forward in lung cancer;

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Vtesse gets a BTD on Niemann Pick drug. Release | Follow @JohnCFierce

@DamianFierce: man with lots of money has no regrets about making more of it. More from Bloomberg | Follow @DamianFierce

> Recro Pharma ($REPH) posted positive Phase II results for its intravenous treatment for post-surgical pain, putting the company on track to start Phase III development later this quarter. More

> GlaxoSmithKline ($GSK) and oncology partner Immunocore have selected their first candidate in a T cell receptor alliance, planning a clinical trial in non-small cell lung cancer. Item

> ChemoCentryx's ($CCXI) lead treatment met its primary endpoint in a Phase II treatment on the rare anti-neutrophil cytoplasmic antibody-associated vasculitis, and the company is planning a Phase III study later this year. News

Medical Device News

@FierceMedDev: Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: This question has been on my mind for a while. What does the "F" in F. Michael Ball stand for? More | Follow @EmilyWFierce

@VarunSaxena2: Medtronic CEO ambivalent about competing with Google, despite budding robotic surgery rivalry. FierceMedicalDevices story | Follow @VarunSaxena2

> Brain app startup settles with FTC over false product claims. Article

> Benvenue secures $60M in debt and equity to accelerate commercialization of its spinal implants. More

> NEA partner outlines challenging med tech VC landscape heading into 2016. Editor's corner

Pharma News

@FiercePharma: Study finds some docs are not strongly recommending HPV vaccines for preteens. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. Article | Follow @EricPFierce

@CarlyHFierce: UPDATED: Former Valeant CFO Schiller to step in for hospitalized CEO Pearson. Report | Follow @CarlyHFierce

> Takeda snatches Baxalta plant to produce Entyvio in U.S. Story

> No M&A? No problem, Actelion says as it rolls out $160K-plus Uptravi. Article

> Rapid-fire pharma M&A could stall a bit in 2016: Bloomberg. More

Biotech Research News

> Cannabinoid drug reduces epileptic seizures in hard-to-treat children. Item

> CRISPR/Cas9 trifecta: Researchers correct genetic defect that triggers Duchenne muscular dystrophy. Report

> Mayo Clinic researchers tackle age-related stem cell dysfunction and metabolic disease. More

> Gut bacteria plays a big role in regulating impact of anti-inflammatory NSAIDs. Story

> UNC team spotlights Dicer as a new target for brain cancers. Article

Vaccines News

> Study finds some docs are not strongly recommending HPV vaccines for preteens. More

> Bavarian Nordic files for Nasdaq IPO. News

> Emergex to use Midatech nanoparticle tech for vaccines against infectious diseases. Story

> Norway's Bionor tests drug-vaccine combo against HIV. Item

> China approves Sinovac's vaccine for hand, foot and mouth disease. Article

Pharma Marketing News

> Actelion slaps $160K-plus price tag on new PAH med Uptravi. Item

> Native advertising for pharma: Winning format or slippery slope to regulatory headaches? Report

> Boosted by CV data, Lilly's Jardiance grabs market share from J&J, AZ. Story

> FDA sends fewer drug promotion action letters in 2015--but is that a good thing for pharma? More

> Novartis matches respiratory rivals with 'smart inhaler' collaboration. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.